vs

Side-by-side financial comparison of Ascendis Pharma A/S (ASND) and Life360, Inc. (LIF). Click either name above to swap in a different company.

Ascendis Pharma A/S is the larger business by last-quarter revenue ($267.3M vs $146.0M, roughly 1.8× Life360, Inc.). On growth, Ascendis Pharma A/S posted the faster year-over-year revenue change (42.3% vs 26.4%). Over the past eight quarters, Ascendis Pharma A/S's revenue compounded faster (60.7% CAGR vs 36.6%).

Growth hormone therapy refers to the use of growth hormone (GH) as a prescription medication—it is one form of hormone therapy. Growth hormone is a peptide hormone secreted by the pituitary gland that stimulates growth and cell reproduction. In the past, growth hormone was extracted from human pituitary glands. Growth hormone is now produced by recombinant DNA technology and is prescribed for a variety of reasons. GH therapy has been a focus of social and ethical controversies for 50 years.

Life360, Inc. develops family-focused safety and connectivity platforms. Core offerings include real-time location sharing, emergency alerts, driving behavior analysis tools and identity theft protection. It serves consumer markets across North America, Europe and Asia-Pacific, with most revenue from tiered premium subscription plans.

ASND vs LIF — Head-to-Head

Bigger by revenue
ASND
ASND
1.8× larger
ASND
$267.3M
$146.0M
LIF
Growing faster (revenue YoY)
ASND
ASND
+16.0% gap
ASND
42.3%
26.4%
LIF
Faster 2-yr revenue CAGR
ASND
ASND
Annualised
ASND
60.7%
36.6%
LIF

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ASND
ASND
LIF
LIF
Revenue
$267.3M
$146.0M
Net Profit
$129.7M
Gross Margin
90.5%
75.1%
Operating Margin
6.1%
Net Margin
88.8%
Revenue YoY
42.3%
26.4%
Net Profit YoY
1425.9%
EPS (diluted)
$1.53

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASND
ASND
LIF
LIF
Q4 25
$267.3M
$146.0M
Q3 25
$230.7M
$124.5M
Q2 25
$170.7M
$115.4M
Q1 25
$109.0M
$103.6M
Q4 24
$187.8M
$115.5M
Q3 24
$62.5M
$92.9M
Q2 24
$38.9M
$84.9M
Q1 24
$103.6M
$78.2M
Net Profit
ASND
ASND
LIF
LIF
Q4 25
$129.7M
Q3 25
$-65.9M
$9.8M
Q2 25
$-42.0M
$7.0M
Q1 25
$-102.2M
$4.4M
Q4 24
$8.5M
Q3 24
$-107.1M
$7.7M
Q2 24
$-118.1M
$-11.0M
Q1 24
$-141.5M
$-9.8M
Gross Margin
ASND
ASND
LIF
LIF
Q4 25
90.5%
75.1%
Q3 25
89.5%
78.0%
Q2 25
80.1%
78.4%
Q1 25
82.6%
80.6%
Q4 24
91.9%
74.0%
Q3 24
80.6%
75.4%
Q2 24
68.2%
75.0%
Q1 24
92.1%
76.7%
Operating Margin
ASND
ASND
LIF
LIF
Q4 25
6.1%
Q3 25
5.1%
4.6%
Q2 25
-33.5%
1.7%
Q1 25
-103.2%
2.1%
Q4 24
4.9%
Q3 24
-167.3%
-5.3%
Q2 24
-370.2%
-2.8%
Q1 24
-51.2%
-8.2%
Net Margin
ASND
ASND
LIF
LIF
Q4 25
88.8%
Q3 25
-28.5%
7.9%
Q2 25
-24.6%
6.1%
Q1 25
-93.7%
4.2%
Q4 24
7.4%
Q3 24
-171.5%
8.3%
Q2 24
-303.9%
-12.9%
Q1 24
-136.6%
-12.5%
EPS (diluted)
ASND
ASND
LIF
LIF
Q4 25
$1.53
Q3 25
$0.11
Q2 25
$0.08
Q1 25
$0.05
Q4 24
$0.14
Q3 24
$0.09
Q2 24
$-0.15
Q1 24
$-0.14

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASND
ASND
LIF
LIF
Cash + ST InvestmentsLiquidity on hand
$665.3M
$494.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$-175.8M
$548.2M
Total Assets
$1.4B
$959.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASND
ASND
LIF
LIF
Q4 25
$665.3M
$494.3M
Q3 25
$582.2M
$455.7M
Q2 25
$533.6M
$432.7M
Q1 25
$559.4M
$168.9M
Q4 24
$604.3M
$159.2M
Q3 24
$675.6M
$159.0M
Q2 24
$279.4M
$160.8M
Q1 24
$345.9M
$73.4M
Total Debt
ASND
ASND
LIF
LIF
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
$5.2M
Stockholders' Equity
ASND
ASND
LIF
LIF
Q4 25
$-175.8M
$548.2M
Q3 25
$-188.0M
$391.4M
Q2 25
$-202.6M
$366.7M
Q1 25
$-205.0M
$376.3M
Q4 24
$-114.2M
$358.5M
Q3 24
$-105.1M
$339.7M
Q2 24
$-346.8M
$326.7M
Q1 24
$-257.2M
$239.8M
Total Assets
ASND
ASND
LIF
LIF
Q4 25
$1.4B
$959.7M
Q3 25
$1.2B
$787.5M
Q2 25
$1.2B
$753.6M
Q1 25
$1.1B
$455.4M
Q4 24
$1.3B
$441.6M
Q3 24
$1.2B
$427.4M
Q2 24
$819.0M
$405.9M
Q1 24
$866.7M
$318.8M
Debt / Equity
ASND
ASND
LIF
LIF
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
0.02×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASND
ASND
LIF
LIF
Operating Cash FlowLast quarter
$58.2M
$36.8M
Free Cash FlowOCF − Capex
$36.6M
FCF MarginFCF / Revenue
25.1%
Capex IntensityCapex / Revenue
0.2%
Cash ConversionOCF / Net Profit
0.28×
TTM Free Cash FlowTrailing 4 quarters
$86.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASND
ASND
LIF
LIF
Q4 25
$58.2M
$36.8M
Q3 25
$26.4M
Q2 25
$13.3M
Q1 25
$-15.5M
$12.1M
Q4 24
$-330.7M
$12.3M
Q3 24
$6.3M
Q2 24
$3.3M
Q1 24
$-109.7M
$10.7M
Free Cash Flow
ASND
ASND
LIF
LIF
Q4 25
$36.6M
Q3 25
$25.6M
Q2 25
$12.7M
Q1 25
$11.9M
Q4 24
$11.2M
Q3 24
$6.3M
Q2 24
$3.2M
Q1 24
FCF Margin
ASND
ASND
LIF
LIF
Q4 25
25.1%
Q3 25
20.6%
Q2 25
11.0%
Q1 25
11.5%
Q4 24
9.7%
Q3 24
6.8%
Q2 24
3.8%
Q1 24
Capex Intensity
ASND
ASND
LIF
LIF
Q4 25
0.2%
Q3 25
0.6%
Q2 25
0.6%
Q1 25
0.1%
Q4 24
1.0%
Q3 24
0.0%
Q2 24
0.1%
Q1 24
0.0%
Cash Conversion
ASND
ASND
LIF
LIF
Q4 25
0.28×
Q3 25
2.70×
Q2 25
1.90×
Q1 25
2.75×
Q4 24
1.45×
Q3 24
0.83×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons